To evaluate the efficacy and safety of subcutaneous and intravenous abatacept.
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000013440
- Lead Sponsor
- Osaka Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded if they were previously treated with biological DMARDs.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of patients completed 36 weeks with SC abatacept 2 weeks dose intervals.
- Secondary Outcome Measures
Name Time Method